CJC-1295 / GHRP-2 Blend
A research peptide blend combining CJC-1295 (no DAC) and GHRP-2, two growth hormone secretagogues that act on distinct receptor pathways (GHRH-R and GHS-R1a) to synergistically amplify pituitary GH release. Preclinical studies suggest cooperative effects on body composition, cardiac function, and immune regulation.
CJC-1295 (Mod GRF 1-29) and GHRP-2 are two growth hormone secretagogues that target complementary receptor systems on anterior pituitary somatotrophs. CJC-1295 activates the GHRH receptor via the cAMP/PKA signaling cascade, while GHRP-2 binds the growth hormone secretagogue receptor (GHS-R1a), engaging Gq/11-coupled calcium mobilization.
Mechanism of Action
The synergy between CJC-1295 and GHRP-2 arises from their action on two mechanistically distinct arms of the GH axis. CJC-1295, as a GHRH analogue, binds the GHRH receptor on pituitary somatotrophs and stimulates GH gene transcription and secretion through cyclic AMP signaling. GHRP-2 acts through the ghrelin/GHS-R1a pathway, which operates via phospholipase C and intracellular calcium release. Additionally, GHRP-2 suppresses somatostatin tone at the hypothalamic level, removing a key brake on GH secretion.
When co-administered, CJC-1295 maintains physiologic pulsatile GH secretion patterns even under continuous stimulation (Ionescu & Frohman, 2006), while GHRP-2 elevates the baseline from which those pulses originate. This dual-receptor activation model produces GH output that exceeds the additive sum of either peptide alone.
Reconstitution Calculator
CJC-1295 / GHRP-2 Blend
CJC-1295 (Mod GRF 1-29) and GHRP-2 are two growth hormone secretagogues that tar
Set up a clean workspace with all supplies ready.
7x / week for weeks
Research
Cardiac Function
The growth hormone secretagogue receptor (GHS-R1a) was identified in cardiac tissue, where GHRP-2 and related peptides exert direct cardioprotective effects independent of GH release (Bodart et al., 1999). This finding expanded the understood role of GHS-R agonists beyond simple GH secretion.
Immune System and Thymus Regeneration
Both GH-releasing pathways have been linked to immune reconstitution. Growth hormone and ghrelin signaling promote thymic regeneration in aged animal models, restoring T-cell output and improving immune surveillance (Taub et al., 2010). The combination of GHRH-pathway and ghrelin-pathway stimulation may offer complementary immunomodulatory benefits.
Metabolic Effects
GHRP-2 stimulates appetite through ghrelin receptor activation, and obese subjects have been shown to respond to its orexigenic effects (Laferrere et al., 2006). When paired with the metabolic effects of elevated GH from CJC-1295, the blend's combined action favors lean body mass accrual over fat deposition, with downstream improvements in insulin sensitivity.
Growth Hormone Stimulation
CJC-1295 has been shown to produce prolonged stimulation of GH and IGF-1 secretion in healthy adults, with sustained elevations lasting several days after a single administration (Teichman et al., 2006). Importantly, pulsatile GH secretion is preserved even during continuous CJC-1295 exposure, distinguishing it from exogenous GH administration (Ionescu & Frohman, 2006).
Muscle Protection
GHRP-2 has demonstrated direct protective effects on skeletal muscle. In myocyte studies, GHRP-2 attenuated dexamethasone-induced expression of the muscle-specific ubiquitin ligases Atrogin-1 and MuRF1, key mediators of muscle protein degradation (Yamamoto et al., 2008). This anti-catabolic activity suggests potential applications in muscle-wasting conditions.
Safety Profile
In preclinical and early clinical studies, both components have shown generally favorable safety profiles. CJC-1295 (no DAC) is associated with transient injection-site reactions and flushing. GHRP-2 may cause transient increases in appetite, cortisol, and prolactin at higher doses. The combination has not been associated with unique adverse effects beyond those of the individual components. Long-term safety data in humans remain limited, and all findings are from research settings.
Pharmacokinetic Profile
CJC-1295 / GHRP-2 Blend — Pharmacokinetic Curve
Subcutaneous injectionQuick Start
- Route
- Subcutaneous injection
Research Protocols
subcutaneous Injection
Administered via subcutaneous injection.
Interactions
Peptide Interactions
CJC-1295 has been shown to produce prolonged stimulation of GH and IGF-1 secretion in healthy adults, with sustained elevations lasting several days after a single administration ([Teichman et al.
The combination of GHRH-pathway and ghrelin-pathway stimulation may offer complementary immunomodulatory benefits.
Additionally, GHRP-2 suppresses somatostatin tone at the hypothalamic level, removing a key brake on GH secretion.
What to Expect
What to Expect
Rapid onset expected; half-life of CJC-1295 (no DAC): ~30 minutes; GHRP-2: ~1-2 hours indicates fast-acting pharmacokinetics
Due to short half-life (CJC-1295 (no DAC): ~30 minutes; GHRP-2: ~1-2 hours), effects are expected per-dose; consistent daily administration maintains...
Regular administration schedule required; effects are dose-dependent and do not persist between doses
Quality Indicators
What to look for
- Well-established safety profile
- Multiple peer-reviewed studies available
Caution
- Injection site reactions reported
Frequently Asked Questions
References (6)
- [1]Ionescu M, Frohman LA Pulsatile secretion of growth hormone persists during continuous stimulation by CJC-1295 J Clin Endocrinol Metab (2006)
- [2]Yamamoto D et al GHRP-2 directly acts on myocytes to attenuate dexamethasone-induced expressions of Atrogin-1 and MuRF1 Life Sci (2008)
- [3]Bodart V et al Identification and characterization of a new growth hormone-releasing peptide receptor in the heart Circ Res (1999)
- [4]Taub DD et al Rejuvenation of the aging thymus: growth hormone-mediated and ghrelin-mediated signaling pathways Curr Opin Pharmacol (2010)
- [5]Teichman SL et al Prolonged stimulation of GH and IGF-I secretion by CJC-1295 in healthy adults J Clin Endocrinol Metab (2006)
- [6]Laferrere B et al Obese subjects respond to the stimulatory effect of the ghrelin agonist GHRP-2 on food intake Obesity (2006)
CJC-1295 DAC
CJC-1295 DAC is a synthetic growth hormone-releasing hormone (GHRH) analogue consisting of the first 29 amino acids of GHRH, conjugated with a drug affinity complex (DAC) that extends its plasma half-life to approximately 6-8 days.
CJC-1295 / GHRP-6 Blend
A research peptide blend combining CJC-1295 (no DAC), a GHRH analogue, with GHRP-6, a synthetic ghrelin analogue, to synergistically elevate growth hormone levels through complementary pituitary receptor activation. Preclinical research highlights benefits in wound healing, neuroprotection, and bone health.